Associate Professor, Department of Dermatology, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation PSP Medical College and hospitals, Chennai, Tamil Nadu, India
Immunomodulators,Psoriasis,Biologics,Corticosteroids,Dermatology treatments ,

This in-depth analysis of the prescription patterns of the immunomodulatory drugs in the outpatient dermatologic clinic is aimed at the analysis of the usage of drugs specific to the treatment of inflammatory and autoimmune skin ill. The conditions prevalent throughout the research were psoriasis, atopic dermatitis, and vitiligo, among which the first one was most often treated. The paper reveals that there is a wide variety of immunomodulators that are used including topical agents such as tacrolimus and pimecrolimus, systemic immunosuppressive drugs such as methotrexate and azathioprine and biological agents such as infliximab and ustekinumab. It highlights the role of such medications in the treatment of chronic and intricate conditions, which is an indication of the evolution of the dermatological-related interventions. The results also support the central importance of corticosteroids in dermatology despite the growing number of newer biologic choices. The most prescribed corticosteroids were betamethasone, hydrocortisone, and clobetasol propionate according to which they will remain relevant in the long term because it has proved to be effective and less expensive than biologics. There is also the promise of biologics though they are less frequently prescribed because of the highly concerning cost involved and the necessity of careful monitoring and treatment but their utilization is gradually gaining popularity especially in conditions of severe psoriasis and psoriatic arthritis. To sum up, the given research explains how dermatology is currently changing, transforming the established methods along with new types of biologic treatment. It also supports the fact that there is the necessity of personalized care solutions based on disease severity, patient variables as well as financial issues

9 , 2 , 2019